Program
Aprepitant
Also written as “aprepitant”, “MK0869, aprepitant” and “Aprepitant Injection”.
Its studies are mostly in Depressive Disorder, Major · Vomiting · Nausea · Postoperative Nausea and Vomiting · Pruritus, led by 7 companies.
Drug pageAprepitant: every studyMany companies study it; this page follows only the 27 they lead. All 128 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 210 open or running | phase 4since Sep 21, 2004 | May 2, 2002 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 3since Jul 17, 2024 | Jul 17, 2024 | none ahead |
| Lahore Medical Research Center, LLPits history only | 10 open or running | phase 3since Feb 23, 2024 | Feb 23, 2024 | none ahead |
| LEO Pharmaits history only | 10 open or running | phase 2since Sep 18, 2013 | Sep 18, 2013 | none ahead |
| Nuformix Technologiesits history only | 10 open or running | phase 1since Mar 20, 2019 | Mar 20, 2019 | none ahead |
| Ono Pharmaceuticalits history only | 10 open or running | phase 2since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Apr 10, 2025 | Apr 10, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since May 2, 2002.
- Sep 13, 2005Ono Pharmaceutical’s first study: phase 2 study in NeoplasmsNew to Ono PharmaceuticalOno Pharmaceutical · NCT00212602 · 420 enrolled · Japan
- Jun 14, 2006Phase 3 study in VomitingMerck · NCT00337727 · 848 enrolled
- Jan 6, 20092 phase 1 studiesMerck · NCT00818259, NCT00819039
- Jul 23, 2009Phase 1 study in VomitingMerck · NCT00945321 · 42 enrolled
- Jul 31, 2009Phase 3 study in VomitingMerck · NCT00952341 · 421 enrolled
- Oct 6, 2009Phase 1 study in VomitingMerck · NCT00990821 · 188 enrolled
- May 26, 2011Phase 3 study in VomitingMerck · NCT01362530 · 307 enrolled
- Jul 5, 2012Phase 4 study in NauseaMerck · NCT01636947 · 494 enrolled
- Nov 19, 2012Phase 2 study in Post-operative NauseaMerck · NCT01732458 · 229 enrolled
- Sep 18, 2013LEO Pharma’s first study: phase 2 study in PruritusNew to LEO PharmaLEO Pharma · NCT01963793 · 20 enrolled · Germany
- Mar 20, 2019Nuformix Technologies’ first study: phase 1 study in HealthyNew to Nuformix TechnologiesNuformix Technologies · NCT03889366 · 12 enrolled · United Kingdom
- Feb 23, 2024Lahore Medical Research Center, LLP’s first study: phase 3 study in Primary DysmenorrheaNew to Lahore Medical Research Center, LLPLahore Medical Research Center, LLP · NCT06317064 · 40 enrolled · Pakistan
- Jul 17, 2024CSPC Pharmaceutical Group’s first study: phase 3 study in VomitingNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06543966 · 486 planned
- Apr 10, 2025Qilu Pharmaceutical’s first study: phase 3 study in Postoperative Nausea and VomitingNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06932107 · 518 enrolled · China
TargetBeta
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule
Other programs on TACR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elinzanetantrule | Bayer | phase 3 | 24 |
| tradipitantrule | Vanda Pharmaceuticals | phase 3 | 19 |
| fosnetupitantrule | Helsinn Healthcare | phase 3 | 2 |
| HRS5580 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06932107Postoperative Nausea and Vomiting · China | 3 | Completed | Qilu Pharmaceutical | May 28, 2024 | 518 |
| NCT06543966Vomiting | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Mar 28, 2026 | 486 |
| NCT06317064Primary Dysmenorrhea · Pakistan | 3 | Completed | Lahore Medical Research Center, LLP | Oct 31, 2024 | 40 |
| NCT03889366Healthy · United Kingdom | 1 | Completed | Nuformix Technologies | Apr 15, 2019 | 12 |
| NCT01963793Pruritus · Germany | 2 | Completed | LEO Pharma | Jul 2014 | 20 |
| NCT01732458Post-operative Nausea | 2 | Completed | Merck | Sep 26, 2016 | 229 |
| NCT01636947Nausea | 4 | Completed | Merck | Aug 4, 2014 | 494 |
| NCT01362530Vomiting | 3 | Completed | Merck | Mar 14, 2013 | 307 |
| NCT00990821Vomiting | 1 | Completed | Merck | Dec 2005 | 188 |
| NCT00952341Vomiting | 3 | Completed | Merck | Apr 4, 2010 | 421 |
| NCT00945321Vomiting | 1 | Completed | Merck | Mar 2009 | 42 |
| NCT00819039Postoperative Nausea and Vomiting · United States, Brazil, Mexico and more | 1 | Completed | Merck | Mar 12, 2013 | 98 |
| NCT00818259Vomiting | 1 | Terminated | Merck | Jan 20, 2014 | 92 |
| NCT00337727Vomiting | 3 | Completed | Merck | Oct 28, 2008 | 848 |
| NCT00212602Neoplasms · Japan | 2 | Completed | Ono Pharmaceutical | 420 | |
| NCT00092196Nausea | 3 | Completed | Merck | Dec 1, 2004 | 820 |
| NCT00092183Nausea | 4 | Completed | Merck | Dec 1, 2003 | 866 |
| NCT00080444Vomiting | 3 | Completed | Merck | Sep 2006 | 50 |
| NCT00048607Depressive Disorder, Major | 3 | Completed | Merck | Dec 31, 2003 | 600 |
| NCT00048594Depressive Disorder, Major | 3 | Completed | Merck | Dec 18, 2003 | 800 |
| NCT00042029Depressive Disorder, Major | 3 | Completed | Merck | Oct 3, 2003 | 324 |
| NCT00035295Depressive Disorder, Major | 3 | Completed | Merck | Dec 5, 2003 | 584 |
| NCT00035282Depressive Disorder, Major | 3 | Completed | Merck | Dec 2003 | 450 |
| NCT00035048Depressive Disorder, Major | 3 | Completed | Merck | Dec 29, 2003 | 540 |
| NCT00035009Depressive Disorder, Major | 3 | Completed | Merck | Dec 22, 2003 | 468 |
| NCT00034983Depressive Disorder, Major | 3 | Completed | Merck | Dec 29, 2003 | 900 |
| NCT00034944Depressive Disorder, Major | 3 | Completed | Merck | Dec 17, 2003 | 495 |
How it is read
Names in the registry
- “aprepitant”, 8 entries
- “Aprepitant”, 4 entries
- “MK0869, aprepitant”, 4 entries
- “Aprepitant Injection”, 2 entries
- “Aprepitant 125 mg”, 2 entries
Codes read as this program: MK0869.
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 9 studies
- Vomiting, 7 studies
- Nausea, 4 studies
- Postoperative Nausea and Vomiting, 3 studies
- Pruritus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.